StreetInsider.com News Articles

Form SCHEDULE 13G/A Compass Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26929784.html

Form SCHEDULE 13G/A Compass Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26929784.html

Form SCHEDULE 13G Compass Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260807/26888396.html

Form SCHEDULE 13G Compass Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260807/26888396.html

Compass Therapeutics (CMPX) PT Raised to $6 at Piper Sandler

Fri, 07 Aug 2026 07:48:52 -0400

Piper Sandler analyst Biren Amin raised the price target on Compass Therapeutics (NASDAQ: CMPX) to $6.00 (from $4.00) while maintaining a Overweight rating.

Form 10-Q Compass Therapeutics, For: Jun 30

Thu, 06 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26879278.html

Form 10-Q Compass Therapeutics, For: Jun 30

Thu, 06 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26879278.html

Compass Therapeutics, Inc. (CMPX) Misses Q2 EPS by 2c

Thu, 06 Aug 2026 07:55:57 -0400

Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q2 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 07:30:00 -0400

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year.
Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.
CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions are actively enrolling patients with triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer based on earlier responses in these indications. Data from

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 07:30:00 -0400

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year.
Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.
CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions are actively enrolling patients with triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer based on earlier responses in these indications. Data from

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 07:30:00 -0400

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year.
Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.
CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions are actively enrolling patients with triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer based on earlier responses in these indications. Data from

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 07:30:00 -0400

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year.
Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.
CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions are actively enrolling patients with triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer based on earlier responses in these indications. Data from

Form 8-K Compass Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:30:00 -0400
si-local-file:///var/storage/secattach/20260806/26878829.html

Form 8-K Compass Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:30:00 -0400
si-local-file:///var/storage/secattach/20260806/26878829.html

Leerink Assumes Compass Therapeutics (CMPX) at Outperform

Tue, 21 Jul 2026 16:49:43 -0400

Leerink analyst Asthika Goonewardene assumes coverage on Compass Therapeutics (NASDAQ: CMPX) with a Outperform rating and a price target of $4.00.

For an analyst ratings summary and ratings history on Compass Therapeutics click here. For more ratings news on Compass Therapeutics click here.

Shares of Compass Therapeutics closed at $2.02 yesterday.

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Fri, 17 Jul 2026 10:42:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig

Form 8-K Compass Therapeutics, For: Jul 01

Wed, 01 Jul 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260701/26721868.html

Form 8-K Compass Therapeutics, For: Jul 01

Wed, 01 Jul 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260701/26721868.html